PhRMA spotlights hopeful efforts amidst despair in Alzheimer's
This article was originally published in Scrip
Executive Summary
With the news lately discouraging in the race to find an effective treatment and potential cure for Alzheimer's disease after two major drugs, Lilly's solanezumab, and bapineuzumab, from Pfizer, Janssen and Elan, failed in Phase III trials – with the latter medicine's program being shut down altogether – some hope is in order.